glp-1 indigestion Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1 | Summary

Giuseppe Arena, University of Luxembourg, Luxembourg Updates Copyright 2021 Kramer

The data does not show superior weight loss with morning versus evening timing

Compared with a group of people with a similar set of clinical characteristics matched closely on demographic factors such as age and ethnicity, treatment indicators such as average body mass index and diabetes prevalence, history of treatments such as bariatric surgery and prevalence of related comorbidities the analysis found that those on GLP-1s lost about twice as much weight

At Parexel, over the past five years, we have completed more than 60 Phase I to IV studies testing GLP-1s, amycretins, and multi-agonists in obesity, type 2 diabetes, cardiovascular diseases, and metabolic dysfunction-associated steatohepatitis (MASH)